

# Eligibility



## Eligibility Criteria

The British Association of Dermatologists (BAD) recommend that **all psoriasis patients** in the UK should be registered with us. The following is our eligibility criteria.



**Chronic plaque or generalised pustular psoriasis**



**Written informed consent**



**Under care of a dermatologist**

## Treatments

Patients must be **starting** or **switching to** one of these drugs, **for treatment of their psoriasis**, in the **last 6 months** to be eligible for our conventional, biologic or small molecule cohorts:



CONVENTIONAL	BIOLOGIC	SMALL MOLECULE
✓ <b>Acitretin</b>	✓ <b>Bimzelx</b> (bimekizumab)	✓ <b>Sotyktu</b> (deucravacitinib)
✓ <b>Ciclosporin</b>	✓ <b>Cosentyx</b> (secukinumab)	
✓ <b>Fumaric acid esters</b>	✓ <b>Ilumetri</b> (tildrakizumab)	
✓ <b>Hydroxycarbamide</b>	✓ <b>Skyrizi</b> (risankizumab)	
✓ <b>Methotrexate</b>	✓ <b>Taltz</b> (ixekizumab)	
✓ <b>Systemic oral PUVA</b>	✓ <b>Tremfya</b> (guselkumab)	

## PASI and DLQI



Conventional patients must have a **PASI of 10 or more** and a **DLQI of 11 or more** (unless switching between conventional therapies). There is no minimum score for biologic or small molecule patients (but we still require a PASI and DLQI).

Patients entering either the small molecule or conventional cohorts must be naive to biologic therapy.

## Paediatric Patients



If the patient is **under the age of 16 at the time of consent**, and starting any **systemic treatment for psoriasis**, the patient will be eligible for BADBIR. Conventional patients **do not** need to meet the DLQI score criteria

